Novo Nordisk expands obesity business in spite of obstacles

Pharmaceutical company Novo Nordisk has attained decent growth in its obesity business despite the fact that it has hardly expanded in the US market.

Photo: Stine Tidsvilde

Following a series of unimpressive quarters, Danish pharmaceutical company Novo Nordisk's obesity business is expanding again.

The industry has great expectations for this leg of the business, but so far, it only contains the treatment Saxenda which grew 9 percent in local currency over the course of Q1 to generate sales worth just over DKK 1.5bn (USD 242m).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs